NovellusDx Raises $10M For Cancer Diagnostics Technology

December 28, 2015 | Israeli biopharmaceutical company NovellusDx has raised $10 million to further develop its cancer treatments. It has been previously reported that the company has already raised two seed rounds of $8 million each, and will use the current funds towards clinical trials of its diagnostic technology which identifies tumor-specific genetic mutations, regardless of whether the mutation has previously been linked to a tumor type. Their live cell assay also measures the impact of a drug on a specific tumor, and in particular, the drug’s effect on cell signaling pathways. Founded in 2012 and led by CEO Haim Gil-Ad, NovellusDx is one of a number of life science companies in the Jerusalem Bio-Park working on genetics-based personalized medicine.